CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States.
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 1.43, read 2026-11-05
Ethical passes the values gate
Price5.32 USD
Fair valueUnder review
Ethical score81.9/100
Our investment reviews on this name
2026-11-04Read Distribution5.56-4.3% to today ✓Accumulation gives way to Distribution after a 31% slide in 7 days
2026-10-28Read Accumulation8.00-33.5% to today Markdown gives way to Accumulation after an 8% rise in 4 weeks
2026-10-02Read Markdown7.42-28.3% to today ✓Markup gives way to Markdown after a 10% slide in 5 weeks
2026-08-25Read Markup8.28-35.7% to today Markdown gives way to Markup after a 5% rise in 4 weeks
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
CorMedix Inc. holds its Distribution at $5.32. Elevated stress, defensive posture warranted, held for 1 days.
As held on the ledger · 2026-11-06
Phase
Distribution · caution
Quantitative state
Elevated stress, defensive posture warranted, held for 1 days
Price at the screen
$5.32
Valuation
3.73 trailing · 21.83 forward price to earnings
Values screen
PASS· score 81.9
Beta
1.41
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
23.94%
Below 33%
Interest-bearing debt is just 23.9% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
23.88%
Below 33%
Cash held in interest-bearing accounts and securities is 23.9% of assets, under the one-third limit.
Pass
Receivables
0.00%
Below 49%
Money owed to the company is 0.0% of assets, under the 49% limit.
Pass
Revenue purity
1.23%
Below 5%
Only 1.2% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
CorMedix clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 24%, inside the ~33% line, and interest is about 1% of its income, under the ~5% line, so it passes.
Read as at 2026-11-07. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when CRMD's ethical verdict changes
Today CRMD passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Fair value under review. Our model's value is 2.13x the price, above our 2.00x limit. We show no fair value, margin of safety or value read built on it until the review clears.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
A Real, Dated Position
Titan Case StudyActive
We put real conviction behind this one: a position we track in the open, reported honestly whether it works or not. This is not just analysis.
Entered2026-07-01
Entry price$8.36
Entry phaseAccumulation
Now · 2026-11-06$5.32
Since entry-36.4%
ThesisAccumulation regime in FDA-approved healthcare micro-cap. Smart money loading before crowd notices. Monitor for markup transition.
A real, dated position · reported honestly whether it works or not. Analysis, not advice.
Where & How to Trade
CRMD trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-07Distribution$5.32+1.7%Entry 13
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 1.7% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading bullish. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (6 analysts) rates it none, with a mean price target of $15. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-06Distribution$5.23-7.6%Entry 12
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 7.6% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading bullish. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (6 analysts) rates it none, with a mean price target of $15. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-05Distribution$5.66+1.8%Entry 11
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 1.8% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading bullish. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (6 analysts) rates it none, with a mean price target of $15. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from accumulation to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 30.5% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading bullish. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (6 analysts) rates it none, with a mean price target of $15.
2026-10-28Accumulation · changed$8.00+5.7%Entry 9
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 5.7% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading bullish. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (6 analysts) rates it strong buy, with a mean price target of $15.
2026-10-21Markdown$7.57+2.4%Entry 8
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 2.4% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (6 analysts) rates it strong buy, with a mean price target of $15.
2026-10-14Markdown$7.39-0.4%Entry 7
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.4% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (6 analysts) rates it strong buy, with a mean price target of $15.
2026-10-02Markdown · changed$7.42-10.4%Entry 6
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 10.4% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (6 analysts) rates it strong buy, with a mean price target of $15.
2026-08-25Markup · changed$8.28+5.2%Entry 5
The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 5.2% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (5 analysts) rates it buy, with a mean price target of $15.
2026-07-25Markdown · changed$7.87-6.5%Entry 4
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 6.5% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (5 analysts) rates it buy, with a mean price target of $15.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
